DMAA · Drugs Made In America Acquisition Corp.
$10.71
At close · Jul 29
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management plans to address this uncertainty through a Business Combination. There is no assurance that the Company’s plans to raise capital or to consummate a Business Combination will be successful within the Combination Period.”View the 10-Q filed May 14, 2026
Market Cap
$260.01M
Shares
24.28M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Roger Bendelac | Chief Executive Officer | Appointed | 2026-03-06 |
| Lynn Stockwell | member of the Board | Resigned | 2026-03-06 |
| Lynn Stockwell | Executive Chair of the Board | Resigned | 2026-03-06 |
| Lynn Stockwell | Chief Executive Officer | Resigned | 2026-03-06 |
Key facts
CIK
2028614
CUSIP
G2847J104
13F (30d)
1 filings
1 filers